Our findings strongly suggest that IL-17A serves as an inflammatory cytokine to promote PDL1 expression, and targeting of IL-17A and PDL1 enhances tumor-specific immune responses and breaks tolerance to tumor antigens. The gene discussed is IL17A; the disease is neoplasm.